NASDAQ: BSEMBiostem Technologies Inc Stock
$4.14+0.26 (+6.7%)
Updated Sep 25, 2026
BSEM Price
$4.14
Fair Value Price
-$2.82
Market Cap
$73.90M
52 Week Low
$2.25
52 Week High
$5.44
P/E
N/A
P/B
2.68x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
N/A
Earnings
N/A
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
0.77
Operating Cash Flow
N/A
Beta
-0.74
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
BSEM Overview
BioStem Technologies, Inc. engages in the development, manufacturing, and commercialization of placental-derived allografts for advanced wound care and regenerative therapies in the United States. It offers Vendaje, a structural tissue allograft used as a protective covering for soft tissue wounds; Vendaje AC, a thicker structural tissue allograft used as a protective covering for soft tissue wounds; Vendaje OPTIC, a structural tissue allograft used as a protective covering during the repair of ocular surfaces; American Amnion AC, a human connective tissue matrix for homologous use; and American Amnion, a human connective tissue matrix for homologous use. The company was formerly known as Caribbean International Holdings Inc. and changed its name to BioStem Technologies, Inc. in August 2014. BioStem Technologies, Inc. was incorporated in 2006 and is based in Fort Lauderdale, Florida.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine BSEM's potential to beat the market
DSell
- Stocks with a Zen Rating of Sell (D) had an average loss of -6.47% per year. Learn More
Zen Rating Component Grades
F
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
BSEM
Ranked#281 of 464
Ranked#281 of 464
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $9.77 | A | |
| $7.75 | A | |
| $360.85 | A |
Be the first to know about important BSEM news, forecast changes, insider trades & much more!
BSEM News
Overview
Due Diligence Score
–
Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how BSEM scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
BSEM ($4.14) is overvalued by 246.89% relative to our estimate of its Fair Value price of -$2.82 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
BSEM ($4.14) is not significantly undervalued (246.89%) relative to our estimate of its Fair Value price of -$2.82 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
BSEM is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
There are 30 more BSEM due diligence checks available for Premium users.
Valuation
BSEM fair value
Fair Value of BSEM stock based on Discounted Cash Flow (DCF)
Price
$4.14
Fair Value
-$2.82
Undervalued by
246.89%
BSEM ($4.14) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
BSEM ($4.14) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
BSEM price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
2.68x
Industry
5.19x
BSEM is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
BSEM's financial health
Profit margin
Revenue
$7.9M
Net Income
-$9.0M
Profit Margin
-113.6%
Assets to liabilities
Assets
$48.8M
Liabilities
$21.2M
Debt to equity
0.77
BSEM's short-term liabilities ($21.20M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
BSEM's short-term assets ($20.78M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
BSEM's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$5.5M
Investing
-$56.1k
Financing
-$1.1M
BSEM vs Biotech Stocks
Biostem Technologies Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.